SLStanislav G. Leontyev

Stanislav G. Leontyev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stanislav G. Leontyev has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plantar vein thrombosis: Clinical presentation, diagnosis, treatment

    by D. A. Churikov, S. G. Leontyev, O. V. Dzhenina, V. N. Lobanov, V. Yu. Bogachev

    Plantar vein thrombosis is an underdiagnosed and, therefore, underestimated pathology with subsequent complications of various degrees of severity. However, the close anatomical relationship between the plantar veins and the superficial and deep leg veins can lead to proximal thrombus propagation with all the consequences that come with it, including fatal pulmonary embolism. The main manifestation of plantar vein thrombosis is pain that worsens with walking, which is an obvious reason to see a surgeon or orthopedic traumatologist. As a significant number of such patients have anatomical foot deformities of varying severity, the mostlikely diagnoses are platypodia, plantar fasciitis, osteoarthritis, etc., followed by orthopedic correction and prescription of nonsteroidal anti-inflammatory drugs. It is apparent that in some cases the treatment is partially successful, which confirms the “correctness” of the diagnosis. At the same time, missed plantar vein thrombosis can reappear, and its consequences can negatively impact the calf musculovenous pump function which is the primary mechanism of centripetal blood flow from the lower extremities. This article presents a case report of a 73-old-patient D. with moderate plantar pain in his left foot in the region closer to the calcaneal tuberosity, which increases with walking. An ultrasound examination demonstrated an occlusive thrombosis of theleft foot medial andlateral plantar veins. The prescribed therapy included rivaroxaban, 15 mg twice daily with food for 3 weeks, followed by switching to a single daily dose of 20 mg for 3 months, wearing of Bauerfeind VenoTrain micro compression stockings, knee high, class 2 (Germany), and foot correction with orthopaedic appliances. After 3-month therapy, the ultrasound examination showed signs of successful recanalization of thrombotic masses in the medial andlateral plantar veins of theleft lower extremity. It should be highlighted that routine ultrasound is the best method used to diagnose plantar vein thrombosis.

  • Open Access

    The Safety of Non‐immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE

    by Stanislav G. Leontyev, Elena B. Yarovaya, Vladimir A. Kutsenko, Oleg E. Ivlev, Anna G. Soplenkova, Andrey M. Semenov, Mikhail P. Semenov, Sergey V. Ivanov, Yulia A. Romashova, Sergey S. Markin

    Background and Aims: Major bleedings are the most limiting factor of the usage of thrombolytic agents in pulmonary embolism (PE), especially in elderly patients. Non‐immunogenic staphylokinase is a recombinant staphylokinase with high thrombolytic activity, fibrin selectivity, and low immunogenic properties. We performed a post hoc analysis of safety outcomes in elderly patients with massive PE over 60 years' old who received non‐immunogenic staphylokinase in FORPE trial. Methods: A randomized, open‐label, multicenter, parallel‐group, noninferiority FORPE trial was conducted at 23 clinical sites in Russia. A total of 310 patients aged 18 years and older with massive PE proven by computed tomography pulmonary angiography, right ventricular dysfunction, and hemodynamic instability were included. The patients were randomized for treatment either the non‐immunogenic staphylokinase (15 mg) or alteplase (100 mg). Safety outcomes were hemorrhagic stroke, bleeding types 3 and 5 according to BARC classification within 7 days after randomization. Results: No cases of hemorrhagic stroke or major bleeding were registered in the non‐immunogenic staphylokinase group, whereas there were five incidences (5%) of BARC type 3 + 5 bleedings in the alteplase group ( p = 0.03). All major bleedings and fatal hemorrhagic stroke in patients treated with alteplase were registered only in elderly patients over 60 years old. Conclusion: The FORPE trial showed that the treatment of massive PE with hemodynamic instability with the non‐immunogenic staphylokinase was safe in elderly patients over 60 years and can be used in emergency medicine in the real‐world clinical practice. Future trials and PE registries are needed to make a final decision on safety of thrombolytic therapy with the non‐immunogenic staphylokinase in elderly patients. Trial Registration: ClinicalTrials.gov (NCT04688320).


  • Open Access

    Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial

    by S. N. Tereshchenko, E. B. Yarovaya, S. G. Leontiev, I. S. Yavelov, R. M. Shakhnovich, A. D. Erlikh, T. M. Uskach, D. V. Duplyakov, V. A. Kutsenko, O. E. Ivlev, et al.

    Aim. To evaluate the efficacy and safety of single bolus administration of non-immunogenic staphylokinase in comparison with placebo in patients with intermediatehigh risk pulmonary embolism (PE) within the FORPE-2 clinical trial.Material and methods. Non-immunogenic staphylokinase has high thrombolytic activity and fibrin selectivity. The FORPE-2 clinical trial has a multicenter, doubleblind, randomized, placebo-controlled design. In clinical sites, patients (486 in total, with a possible 10% dropout rate) with confirmed PE and evidence of right ventricular dysfunction based on computed tomography pulmonary angiography and an increased risk of hemodynamic instability (intermediate-high-risk PE) will be equally randomized into two groups to receive non-immunogenic staphylokinase or placebo. The study protocol provides inclusion and exclusion criteria, calculation of the required patient sample size, and the study plan. The primary efficacy endpoint will be a composite of all-cause mortality, hemodynamic collapse, and recurrent PE within 30 days of randomization. Safety endpoints will be hemorrhagic stroke during hospitalization and BARC type 3 and 5 bleeding types.Results. The study will provide data on the efficacy and safety of non-immunogenic staphylokinase in patients with intermediate-high risk PE. A report will be compiled with individual data and statistical analysis of the results.


  • Open Access

    Thrombosis in the postpartum period

    by M.A. Kurtser, R.G. Shmakov, S.G. Leontiev, Moscow Llc “First Phlebological Center”, T.Yu. Semenova, B.A. Konoplev, A.K. Medvedskaya

    Тромбозы в послеродовом периоде

  • Open Access

    Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial

    by A. I. Kirienko, S. G. Leontyev, E. B. Yarovaya, S. I. Konstantinov, B. B. Orlov, Imad Meray, D. V. Duplyakov, V. E. Oleynikov, E. Yu. Vasilyeva, E. A. Ponomarev, et al.

    Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity and fibrin selectivity.Material and methods. This multicenter, open-label, randomized, comparative clinical trial FORPE in two parallel groups was conducted in 23 clinical centers in Russia. A total of 310 patients aged 18 years and older with hemodynamic instability and computed tomography pulmonary angiography verified massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned in either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg) group. Both medicines were administered intravenously. An independent biostatistician created a randomization sequence using computer-generated random numbers. Randomization was performed using the envelopes. The study was open-label, and emergency unit staff, investigators, and patients were informed about the assigned drug. The primary efficacy endpoint was 7-day all-cause death after randomization. The non-inferiority margin was set at 10% for the difference in 7-day all-cause mortality after randomization between the compared groups. Non-inferiority was tested using the Welch t-test for the primary efficacy endpoint. Secondary efficacy endpoints were analyzed in both the intention-to-treat and per-protocol populations.Results. Of 348 patients screened between December 25, 2020, and July 31, 2023, 310 (89%) were included in the study. Of the total number, 155 (50%) patients were randomized to the non-immunogenic staphylokinase group and 155 (50%) to the alteplase group. In the non-immunogenic staphylokinase group, the primary efficacy endpoint, 7-day all-cause death, was 2% in the intent-to-treat population and 2% in the per-protocol population, whereas in the alteplase group it was 3% (odds ratio (OR) 0,75, 95% confidence interval (CI) 0,11-4,49; p=1,00) and 3% (OR 0,75, 95% CI 0,11-4,52; p=1,00), respectively. The difference in the primary efficacy endpoint was 0,6% (95% CI -2,8 to -4,0) in the intent-to-treat population and 0,6% (95% CI -2,9 to -4,2) in the per-protocol population. Thus, the lower limit of the 95% CI did not cross the non-inferiority margin (pConclusion. Non-immunogenic staphylokinase is at least as effective as alteplase in the treatment of patients with massive pulmonary embolism with hemodynamic instability and has a higher safety profile. Future observational studies of non-immunogenic staphylokinase are needed to continue assessing its safety and efficacy. Given the high safety and efficacy of non-immunogenic staphylokinase, its use should be studied in patients with moderate-to-high risk pulmonary embolism.


  • Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE

    by Alexander I. Kirienko, Stanislav G. Leontyev, Sergey N. Tereschenko, Igor S. Yavelov, Roman M. Shakhnovich, Alexey D. Erlikh, Oleg B. Talibov, Elena B. Yarovaya, Andrey M. Semenov, Michail P. Semenov, et al.


  • Non-Immunogenic Staphylokinase vs Alteplase in Patients with Massive Pulmonary Embolism: the Protocol of a Multiple-Center Open-Label Randomized Trial FORPE

    by A.I. Kirienko, E.B. Yarovaya, V.A. Kutsenko, A.A. Orlovsky, S.V. Ivanov, M.P. Semenov, A.M. Semenov, S.G. Leontiev, S.S. Markin

    ЦЕЛЬ Клинического исследования ФОРПЕ — оценка эффективности и безопасности неиммуногенной стафилокиназы при ее однократном болюсном введении в сравнении с болюсно-инфузионным введением алтеплазы у пациентов с массивной тромбоэмболией легочных артерий. МАТЕРИАЛ И МЕТОДЫ Неиммуногенная стафилокиназа обладает высокой тромболитической активностью и фибринселективностью. Клиническое исследование ФОРПЕ — многоцентровое открытое рандомизированное сравнительное исследование «не меньшей эффективности» (non-inferiority) в двух параллельных группах. На клинических базах пациенты (общее число 310 человек с учетом возможного 10% выбывания) с подтвержденным по данным мультиспиральной компьютерной томография с контрастированием легочных артерий диагнозом «массивная тромбоэмболия легочных артерий» будут поровну рандомизированы методом конвертов на две группы для назначения неиммуногенной стафилокиназы или алтеплазы. В протоколе исследования представлены критерии включения и невключения, расчет объема необходимой выборки пациентов и план проведения исследования. Основной критерий оценки эффективности тромболитической терапии с применением неиммуногенной стафилокиназы или алтеплазы — смерть от всех причин в течение 7 сут. Критерии безопасности — ишемический и геморрагический инсульт в течение 7 сут после тромболизиса и кровотечения по критериям BARC (3-го и 5-го типов). РЕЗУЛЬТАТЫ По итогам исследования будут получены данные об эффективности и безопасности неиммуногенной стафилокиназы у пациентов с массивной тромбоэмболией легочных артерий; составлен отчет с приложениями индивидуальных данных и статистического анализа результатов. Результаты исследования будут опубликованы и представлены на конференциях. РЕГИСТРАЦИЯ Протокол исследования ФОРПЕ утвержден Минздравом России (№16 от 15.01.19 с дополнениями от 05.07.21), Советом по этике Минздрава России (№182 от 04.12.18) и зарегистрирован на clinicaltrials.gov (№NCT04688320, FORPE).